Evaluation of Microglial Activation Using the PET Imaging Ligand [18F]PBR06 in Patients With Amyotrophic Lateral Sclerosis Compared to Healthy Volunteers
The clinical trial conducted by Molecular NeuroImaging aims to assess microglial activation in patients with Amyotrophic Lateral Sclerosis (ALS) using the PET imaging ligand [18F]PBR06. Given the increasing prevalence of neurodegenerative diseases and the need for effective diagnostic tools, this study positions [18F]PBR06 as a potential biomarker for ALS, which could enhance patient stratification and monitoring. The market for ALS therapeutics and diagnostics is growing, with a focus on innovative imaging techniques. The results of this trial may provide a competitive edge in the neuroimaging market, particularly for companies developing ALS therapies or diagnostics. Diligence should focus on the regulatory pathway for [18F]PBR06 and potential partnerships with pharmaceutical companies for further development.
Indication: Healthy Volunteers
Modality: radioligand therapy
Target: Microglial activation in the brain, evaluated using the PET imaging ligand [18F]PBR06.
Sponsor: Molecular NeuroImaging
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: radioligand therapy
View original source fields
Condition raw: Healthy Volunteers, Amyotrophic Lateral Sclerosis
Condition normalized: Healthy Volunteers, Amyotrophic Lateral Sclerosis
Modality raw: radioligand therapy
Modality normalized: radioligand therapy
Target raw: Microglial activation in the brain, evaluated using the PET imaging ligand [18F]PBR06.
Target normalized: Microglial activation in the brain, evaluated using the PET imaging ligand [18F]PBR06.